Table of Contents
Table of Contents 2
List of Tables 8
List of Figures 13
Introduction 14
Global Markets Direct Report Coverage 14
HIV / AIDS Overview 15
Therapeutics Development 16
An Overview of Pipeline Products for HIV / AIDS 16
HIV / AIDS Therapeutics under Development by Companies 18
HIV / AIDS Therapeutics under Investigation by Universities/Institutes 28
Late Stage Products 35
Comparative Analysis 35
Mid Clinical Stage Products 36
Comparative Analysis 36
Early Clinical Stage Products 37
Comparative Analysis 37
Discovery and Pre-Clinical Stage Products 38
Comparative Analysis 38
HIV / AIDS Therapeutics – Products under Development by Companies 39
HIV / AIDS Therapeutics – Products under Investigation by Universities/Institutes 52
Companies Involved in HIV / AIDS Therapeutics Development 78
Bristol-Myers Squibb Company 78
Johnson & Johnson 79
Boehringer Ingelheim GmbH 80
Abbott Laboratories 81
Vical Incorporated 82
Shionogi & Co., Ltd. 83
GlaxoSmithKline plc 84
Nektar Therapeutics 85
Antigenics, Inc. 86
Inovio Biomedical Corporation 87
Bavarian Nordic A/S 88
Gilead Sciences, Inc. 89
VIRxSYS Corporation 90
Merck & Co., Inc. 91
United Biomedical, Inc. 92
Lentigen Corporation 93
Sangamo BioSciences, Inc. 94
Generex Biotechnology Corporation 95
Nanotherapeutics, Inc. 96
Ambrilia Biopharma Inc. 97
Biotron Limited 98
Aphios Corporation 99
Achillion Pharmaceuticals, Inc. 100
Esteve Group 101
InterMune, Inc. 102
Japan Tobacco Inc. 103
Sequoia Pharmaceuticals, Inc. 147
Rottapharm SpA 148
Indus Biotech Private Limited 149
Locus Pharmaceuticals, Inc. 150
Presidio Pharmaceuticals, Inc. 151
Chimerix, Inc. 152
Theraclone Sciences, Inc. 153
Frontier Biotechnologies, Inc. 154
REPLICor Inc. 155
Kainos Medicine, Inc. 156
Viral Genetics, Inc. 157
Concert Pharmaceuticals, Inc. 158
Ferring Pharmaceuticals, Inc. 176
Tibotec Pharmaceuticals Ltd. 177
Kemin Industries, Inc. 178
Heptares Therapeutics Ltd. 179
VIRIOM Ltd. 180
CONRAD 181
ViiV Healthcare 182
Vichem Chemie Research Ltd. 183
ImQuest Life Sciences 184
Tibotec Therapeutics 185
HIV / AIDS – Therapeutics Assessment 186
Assessment by Monotherapy Products 186
Assessment by Combination Products 187
Assessment by Route of Administration 188
Assessment by Molecule Type 191
Drug Profiles 194
Cobicistat - Drug Profile 194
1349572 - Drug Profile 195
Truvada - Drug Profile 197
JTK-303 - Drug Profile 199
JTK-303 - Drug Profile 201
SP-01A - Drug Profile 203
Ampligen - Drug Profile 205
VGV-1 - Drug Profile 206
Quad - Drug Profile 207
Tenofovir + Emtricitabine + Efavirenz - Drug Profile 209
Emtricitabine + Tenofovir Disoproxil Fumarate - Drug Profile 211
Zidovudine + Lamivudine + Nevirapine - Drug Profile 212
Aluvia - Drug Profile 213
Aluvia + Raltegravir - Drug Profile 214
Nevirapine - Drug Profile 216
Emtricitabine + Tenofovir Disoproxil Fumarate + Lopinavir + Ritonavir + Nevirapine - Drug Profile 218
Proleukin + Anti-HIV Therapy - Drug Profile 220
Abacavir + Lamivudine + Zidovudine - Drug Profile 222
Lamivudine + Zidovudine + Nelfinavir - Drug Profile 223
Emtricitabine + Tenofovir Disoproxil Fumarate + Ritonavir + Atazanavir - Drug Profile 225
Emtricitabine + Tenofovir Disoproxil Fumarate + Raltegravir - Drug Profile 226
Emtricitabine + Tenofovir Disoproxil Fumarate + Darunavir + Ritonavir - Drug Profile 227
Erythromycin + Nevirapine + Ampicillin Sodium + Metronidazole - Drug Profile 229
Valacyclovir - Drug Profile 231
Buprenorphine + Naloxone - Drug Profile 233
Prednisone - Drug Profile 234
Raltegravir + Truvada - Drug Profile 235
Stavudine + Lamivudine + Abacavir - Drug Profile 236
Emtricitabine + Tenofovir - Drug Profile 237
Tenofovir - Drug Profile 238
Stavudine + Lamivudine + Nevirapine - Drug Profile 239
Abacavir + Lamivudine + Nevirapine - Drug Profile 241
Zidovudine + Lamivudine + Abacavir - Drug Profile 243
GPO-VIR S + GPO-VIR Z - Drug Profile 244
Raltegravir - Drug Profile 245
GPO-VIR Z - Drug Profile 246
Truvada + Nevirapine - Drug Profile 247
Didanosine + Abacavir + Kaletra - Drug Profile 248
Zidovudine + Lamivudine + Kaletra - Drug Profile 250
Proleukin + Paracetamol + Ibuprofen + Ondansetron + Codeine Phosphate - Drug Profile 252
Proleukin + Paracetamol + Ibuprofen + Metoclopramide + Codeine Phosphate - Drug Profile 254
Isentress + Kaletra - Drug Profile 256
Stavudine + Lamivudine + Nevirapine - Drug Profile 257
Stavudine + Lamivudine + Efavirenz - Drug Profile 259
Abacavir + Lamivudine + Nevirapine - Drug Profile 261
Abacavir + Lamivudine + Efavirenz - Drug Profile 263
Zidovudine + Lamivudine + Nevirapine - Drug Profile 265
Zidovudine + Lamivudine + Efavirenz - Drug Profile 267
Viramune XR - Drug Profile 269
Zovirax - Drug Profile 271
Lopinavir + Ritonavir + Efavirenz - Drug Profile 272
Zalcitabine - Drug Profile 274
Lopinavir + Ritonavir + Zidovudine - Drug Profile 275
Remune - Drug Profile 276
Indinavir + Ritonavir + Abacavir + Didanosine + Proleukin - Drug Profile 278
Darunavir + Ritonavir - Drug Profile 280
Tenofovir Disoproxil Fumarate - Drug Profile 281
Tenofovir + Emtricitabine + Efavirenz - Drug Profile 283
Isentress + Celsentri + Prezista + Norvir + Truvada - Drug Profile 285
Clarithromycin + Ethambutol + Rifabutin - Drug Profile 287
Clarithromycin + Ethambutol + Clofazimine - Drug Profile 289
Viramune + Truvada - Drug Profile 291
Telzir + Norvir + Abacavir + Lamivudine - Drug Profile 293
Sustiva + Epzicom - Drug Profile 295
Atazanavir + Ritonavir + Abacavir + Lamivudine - Drug Profile 296
Lamivudine + Zidovudine + Nelfinavir + Efavirenz - Drug Profile 298
Nevirapine + Lopinavir + Ritonavir - Drug Profile 299
Ritonavir + Saquinavir + Efavirenz - Drug Profile 300
Ziodovudine + Alpha Interferon - Drug Profile 302
Lopinavir + Ritonavir - Drug Profile 303
Zidovudine + Lamivudine + Ritonavir + Indinavir 7 - Drug Profile 304
Enfuvirtide + Raltegravir + Darunavir + Tipranavir + Etravirine + Maraviroc - Drug Profile 306
Indinavir Sulfate + Lamivudine + Zidovudine - Drug Profile 308
Abacavir + Lamivudine + Atazanavir + Ritonavir - Drug Profile 309
Abacavir Sulfate + Didanosine + Efavirenz + Lamivudine + Lopinavir + Nevirapine + Zidovudine - Drug Profile 311
Levocarnitine + Adefovir dipivoxil - Drug Profile 314
Lopinavir + Ritonavir + Nucleoside Reverse Transcriptase Inhibitors + PEG-IFNa 2a + Ribavirin - Drug Profile 315
Nevirapine + Rifampicin + Ethambutol + Isoniazid + Pyrazinamid - Drug Profile 317
Raltegravir + Maraviroc + Tenofovir + Emtricitabine - Drug Profile 319
Viread + Aluvia - Drug Profile 321
Truvada + Nevirapine - Drug Profile 322
Truvada + Zidovudine - Drug Profile 324
Truvada - Drug Profile 326
Abacavir + Lamivudine + Efavirenz - Drug Profile 327
Darunavir + Ritonavir + Raltegravir - Drug Profile 329
Atazanavir + Didanosine + Efavirenz + Emtricitabine + Tenofovir Disoproxil Fumarate + Lamivudine + Lopinavir + Ritonavir + Nevirapine + Stavudine + Zidovudine - Drug Profile 330
Raltegravir + Maraviroc + Emtricitabine + Tenofovir + Lopinavir + Ritonavir - Drug Profile 333
Lopinavir + Ritonavir - Drug Profile 335
Darunavir + Ritonavir - Drug Profile 336
Isentress + Celsentri + Truvada + Kaletra - Drug Profile 337
Truvada + Raltegravir - Drug Profile 339
Fuzeon + Truvada + Kaletra - Drug Profile 341
Abacavir - Drug Profile 343
Abacavir + Lamivudine + Efavirenz - Drug Profile 344
Efavirenz - Drug Profile 345
Etravirine - Drug Profile 346
Valsartan - Drug Profile 347
Viread + Epivir + Sustiva - Drug Profile 348
Zerit + Epivir + Sustiva - Drug Profile 350
Lopinavir + Ritonavir + Lamivudine + Stavudine - Drug Profile 352
Efavirenz + Lamivudine + Stavudine - Drug Profile 354
Efavirenz + Lamivudine + Tenofovir - Drug Profile 356
Lopinavir + Ritonavir + Lamivudine + Tenofovir Disoproxil Fumarate - Drug Profile 358
Intelence + Prezista + Ritonavir - Drug Profile 361
Maraviroc + Antiretroviral Therapy - Drug Profile 363
Lamivudine + Tenofovir + Atazanavir + Ritonavir - Drug Profile 365
572-Trii - Drug Profile 367
Atazanavir Sulphate + Ritonavir - Drug Profile 369
Hepavax-Gene - Drug Profile 370
Reyataz + Cobicistat - Drug Profile 371
Cobicistat + Prezista - Drug Profile 373
Pentamidine - Drug Profile 374
RemuneX - Drug Profile 375
HIV / AIDS Therapeutics – Drug Profile Updates 377
HIV / AIDS Therapeutics – Discontinued Products 390
HIV / AIDS Therapeutics - Dormant Products 398
HIV / AIDS – Product Development Milestones 439
Featured News & Press Releases 439
Appendix 447
Methodology 447
Coverage 447
Secondary Research 447
Primary Research 447
Expert Panel Validation 448
Contact Us 448
Disclaimer 448
List of Tables
Number of Products Under Development for HIV / AIDS, H1 2012 24
Products under Development for HIV / AIDS – Comparative Analysis, H1 2012 25
Number of Products under Development by Companies, H1 2012 27
Number of Products under Development by Companies, H1 2012 (Contd..1) 28
Number of Products under Development by Companies, H1 2012 (Contd..2) 29
Number of Products under Development by Companies, H1 2012 (Contd..3) 30
Number of Products under Development by Companies, H1 2012 (Contd..4) 31
Number of Products under Development by Companies, H1 2012 (Contd..5) 32
Number of Products under Development by Companies, H1 2012 (Contd..6) 33
Number of Products under Development by Companies, H1 2012 (Contd..7) 34
Number of Products under Development by Companies, H1 2012 (Contd..8) 35
Number of Products under Investigation by Universities/Institutes, H1 2012 37
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..1) 38
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..2) 39
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..3) 40
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..4) 41
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..5) 42
Comparative Analysis by Late Stage Development, H1 2012 43
Comparative Analysis by Mid Clinical Stage Development, H1 2012 44
Comparative Analysis by Early Clinical Stage Development, H1 2012 45
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012 46
Products under Development by Companies, H1 2012 47
Products under Development by Companies, H1 2012 (Contd..1) 48
Products under Development by Companies, H1 2012 (Contd..2) 49
Products under Development by Companies, H1 2012 (Contd..3) 50
Products under Development by Companies, H1 2012 (Contd..4) 51
Products under Development by Companies, H1 2012 (Contd..5) 52
Products under Development by Companies, H1 2012 (Contd..6) 53
Products under Development by Companies, H1 2012 (Contd..7) 54
Products under Development by Companies, H1 2012 (Contd..8) 55
Products under Development by Companies, H1 2012 (Contd..9) 56
Products under Development by Companies, H1 2012 (Contd..10) 57
Products under Development by Companies, H1 2012 (Contd..11) 58
Products under Development by Companies, H1 2012 (Contd..12) 59
Products under Investigation by Universities/Institutes, H1 2012 60
Products under Investigation by Universities/Institutes, H1 2012 (Contd..1) 61
Products under Investigation by Universities/Institutes, H1 2012 (Contd..2) 62
Products under Investigation by Universities/Institutes, H1 2012 (Contd..3) 63
Products under Investigation by Universities/Institutes, H1 2012 (Contd..4) 64
Products under Investigation by Universities/Institutes, H1 2012 (Contd..5) 65
Products under Investigation by Universities/Institutes, H1 2012 (Contd..6) 66
Products under Investigation by Universities/Institutes, H1 2012 (Contd..7) 67
Products under Investigation by Universities/Institutes, H1 2012 (Contd..8) 68
Products under Investigation by Universities/Institutes, H1 2012 (Contd..9) 69
Products under Investigation by Universities/Institutes, H1 2012 (Contd..10) 70
Products under Investigation by Universities/Institutes, H1 2012 (Contd..11) 71
Products under Investigation by Universities/Institutes, H1 2012 (Contd..12) 72
Products under Investigation by Universities/Institutes, H1 2012 (Contd..13) 73
Products under Investigation by Universities/Institutes, H1 2012 (Contd..14) 74
Products under Investigation by Universities/Institutes, H1 2012 (Contd..15) 75
Products under Investigation by Universities/Institutes, H1 2012 (Contd..16) 76
Products under Investigation by Universities/Institutes, H1 2012 (Contd..17) 77
Products under Investigation by Universities/Institutes, H1 2012 (Contd..18) 78
Products under Investigation by Universities/Institutes, H1 2012 (Contd..19) 79
Products under Investigation by Universities/Institutes, H1 2012 (Contd..20) 80
Products under Investigation by Universities/Institutes, H1 2012 (Contd..21) 81
Products under Investigation by Universities/Institutes, H1 2012 (Contd..22) 82
Products under Investigation by Universities/Institutes, H1 2012 (Contd..23) 83
Products under Investigation by Universities/Institutes, H1 2012 (Contd..24) 84
Products under Investigation by Universities/Institutes, H1 2012 (Contd..25) 85
Bristol-Myers Squibb Company, H1 2012 86
Johnson & Johnson, H1 2012 87
Boehringer Ingelheim GmbH, H1 2012 88
Abbott Laboratories, H1 2012 89
Vical Incorporated, H1 2012 90
Shionogi & Co., Ltd., H1 2012 91
GlaxoSmithKline plc, H1 2012 92
Nektar Therapeutics, H1 2012 93
Antigenics, Inc., H1 2012 94
Inovio Biomedical Corporation, H1 2012 95
Bavarian Nordic A/S, H1 2012 96
Gilead Sciences, Inc., H1 2012 97
VIRxSYS Corporation, H1 2012 98
Merck & Co., Inc., H1 2012 99
United Biomedical, Inc., H1 2012 100
Lentigen Corporation, H1 2012 101
Sangamo BioSciences, Inc., H1 2012 102
Generex Biotechnology Corporation, H1 2012 103
Nanotherapeutics, Inc., H1 2012 104
Ambrilia Biopharma Inc., H1 2012 105
Biotron Limited, H1 2012 106
Aphios Corporation, H1 2012 107
Achillion Pharmaceuticals, Inc., H1 2012 108
Esteve Group, H1 2012 109
InterMune, Inc., H1 2012 110
Japan Tobacco Inc., H1 2012 111
Progenics Pharmaceuticals, Inc., H1 2012 112
Hadasit Medical Research Services & Development Ltd, H1 2012 113
Avexa Limited, H1 2012 114
Koronis Pharmaceuticals, Inc., H1 2012 115
Trimeris, Inc., H1 2012 116
GeoVax Labs, Inc., H1 2012 117
Hemispherx Biopharma, Inc., H1 2012 118
Celldex Therapeutics, Inc., H1 2012 119
Enzo Biochem, Inc., H1 2012 120
Ardea Biosciences, Inc., H1 2012 121
Medivir AB, H1 2012 122
Bio-Bridge Science, Inc., H1 2012 123
Benitec Ltd., H1 2012 124
ReGenX Biosciences, LLC, H1 2012 125
Mymetics Corporation, H1 2012 126
NanoViricides, Inc., H1 2012 127
Nutra Pharma Corporation, H1 2012 128
Critical Outcome Technologies Inc., H1 2012 129
Pharmasset, Inc, H1 2012 130
CytoGenix, Inc., H1 2012 131
ADVENTRX Pharmaceuticals, H1 2012 132
Starpharma Holdings Limited, H1 2012 133
Immuron Limited, H1 2012 134
Samaritan Pharmaceuticals, Inc., H1 2012 135
BioAlliance Pharma SA, H1 2012 136
Eurocine Vaccines AB, H1 2012 137
Paloma Pharmaceuticals, Inc., H1 2012 138
Antigen Express, Inc., H1 2012 139
SCYNEXIS, Inc., H1 2012 140
Nutri Pharma ASA, H1 2012 141
Neurotune AG, H1 2012 142
BioMAS Ltd., H1 2012 143
Vironova AB, H1 2012 144
ViroStatics, srl, H1 2012 145
Argos Therapeutics, Inc., H1 2012 146
Cytheris SA, H1 2012 147
Altor BioScience Corporation, H1 2012 148
Osel Inc., H1 2012 149
Heat Biologics, Inc., H1 2012 150
AiCuris GmbH & Co. KG, H1 2012 151
Viroblock S.A., H1 2012 152
AlphaVax, Inc., H1 2012 153
ReProtect, Inc., H1 2012 154
Sequoia Pharmaceuticals, Inc., H1 2012 155
Rottapharm SpA, H1 2012 156
Indus Biotech Private Limited, H1 2012 157
Locus Pharmaceuticals, Inc., H1 2012 158
Presidio Pharmaceuticals, Inc., H1 2012 159
Chimerix, Inc., H1 2012 160
Theraclone Sciences, Inc., H1 2012 161
Frontier Biotechnologies, Inc., H1 2012 162
REPLICor Inc., H1 2012 163
Kainos Medicine, Inc., H1 2012 164
Viral Genetics, Inc., H1 2012 165
Concert Pharmaceuticals, Inc., H1 2012 166
Myriad Pharmaceuticals, Inc., H1 2012 167
CytoDyn, Inc., H1 2012 168
GeneCure LLC, H1 2012 169
Oncolys BioPharma Inc., H1 2012 170
Globeimmune, Inc., H1 2012 171
Etubics Corporation, H1 2012 172
Immunocore Limited., H1 2012 173
Canopus BioPharma Incorporated, H1 2012 174
PepTcell Limited, H1 2012 175
TVAX Biomedical, LLC, H1 2012 176
Tobira Therapeutics, Inc., H1 2012 177
Genetic Immunity, LLC, H1 2012 178
Virax Holdings Limited, H1 2012 179
TNI Pharmaceuticals, Inc., H1 2012 180
Medisyn Technologies, Inc., H1 2012 181
Pharis Biotec GmbH, H1 2012 182
Amazon BioTech, H1 2012 183
Ferring Pharmaceuticals, Inc., H1 2012 184
Tibotec Pharmaceuticals Ltd., H1 2012 185
Kemin Industries, Inc., H1 2012 186
Heptares Therapeutics Ltd., H1 2012 187
VIRIOM Ltd., H1 2012 188
CONRAD, H1 2012 189
ViiV Healthcare, H1 2012 190
Vichem Chemie Research Ltd., H1 2012 191
ImQuest Life Sciences, H1 2012 192
Tibotec Therapeutics, H1 2012 193
Assessment by Monotherapy Products, H1 2012 194
Assessment by Combination Products, H1 2012 195
Assessment by Stage and Route of Administration, H1 2012 198
Assessment by Stage and Molecule Type, H1 2012 201
HIV / AIDS Therapeutics – Drug Profile Updates 385
HIV / AIDS Therapeutics – Discontinued Products 398
HIV / AIDS Therapeutics – Discontinued Products (Contd..1) 399
HIV / AIDS Therapeutics – Discontinued Products (Contd..2) 400
HIV / AIDS Therapeutics – Discontinued Products (Contd..3) 401
HIV / AIDS Therapeutics – Discontinued Products (Contd..4) 402
HIV / AIDS Therapeutics – Discontinued Products (Contd..5) 403
HIV / AIDS Therapeutics – Discontinued Products (Contd..6) 404
HIV / AIDS Therapeutics – Discontinued Products (Contd..7) 405
HIV / AIDS Therapeutics – Dormant Products 406
HIV / AIDS Therapeutics – Dormant Products (Contd..1) 407
HIV / AIDS Therapeutics – Dormant Products (Contd..2) 408
HIV / AIDS Therapeutics – Dormant Products (Contd..3) 409
HIV / AIDS Therapeutics – Dormant Products (Contd..4) 410
HIV / AIDS Therapeutics – Dormant Products (Contd..5) 411
HIV / AIDS Therapeutics – Dormant Products (Contd..6) 412
HIV / AIDS Therapeutics – Dormant Products (Contd..7) 413
HIV / AIDS Therapeutics – Dormant Products (Contd..8) 414
HIV / AIDS Therapeutics – Dormant Products (Contd..9) 415
HIV / AIDS Therapeutics – Dormant Products (Contd..10) 416
HIV / AIDS Therapeutics – Dormant Products (Contd..11) 417
HIV / AIDS Therapeutics – Dormant Products (Contd..12) 418
HIV / AIDS Therapeutics – Dormant Products (Contd..13) 419
HIV / AIDS Therapeutics – Dormant Products (Contd..14) 420
HIV / AIDS Therapeutics – Dormant Products (Contd..15) 421
HIV / AIDS Therapeutics – Dormant Products (Contd..16) 422
HIV / AIDS Therapeutics – Dormant Products (Contd..17) 423
HIV / AIDS Therapeutics – Dormant Products (Contd..18) 424
HIV / AIDS Therapeutics – Dormant Products (Contd..19) 425
HIV / AIDS Therapeutics – Dormant Products (Contd..20) 426
HIV / AIDS Therapeutics – Dormant Products (Contd..21) 427
HIV / AIDS Therapeutics – Dormant Products (Contd..22) 428
HIV / AIDS Therapeutics – Dormant Products (Contd..23) 429
HIV / AIDS Therapeutics – Dormant Products (Contd..24) 430
HIV / AIDS Therapeutics – Dormant Products (Contd..25) 431
HIV / AIDS Therapeutics – Dormant Products (Contd..26) 432
HIV / AIDS Therapeutics – Dormant Products (Contd..27) 433
HIV / AIDS Therapeutics – Dormant Products (Contd..28) 434
HIV / AIDS Therapeutics – Dormant Products (Contd..29) 435
HIV / AIDS Therapeutics – Dormant Products (Contd..30) 436
HIV / AIDS Therapeutics – Dormant Products (Contd..31) 437
HIV / AIDS Therapeutics – Dormant Products (Contd..32) 438
HIV / AIDS Therapeutics – Dormant Products (Contd..33) 439
HIV / AIDS Therapeutics – Dormant Products (Contd..34) 440
HIV / AIDS Therapeutics – Dormant Products (Contd..35) 441
HIV / AIDS Therapeutics – Dormant Products (Contd..36) 442
HIV / AIDS Therapeutics – Dormant Products (Contd..37) 443
HIV / AIDS Therapeutics – Dormant Products (Contd..38) 444
HIV / AIDS Therapeutics – Dormant Products (Contd..39) 445
HIV / AIDS Therapeutics – Dormant Products (Contd..40) 446
List of Figures
Number of Products under Development for HIV / AIDS, H1 2012 24
Products under Development for HIV / AIDS – Comparative Analysis, H1 2012 25
Products under Development by Companies, H1 2012 26
Products under Investigation by Universities/Institutes, H1 2012 36
Late Stage Products, H1 2012 43
Mid Clinical Stage Products, H1 2012 44
Early Clinical Stage Products, H1 2012 45
Discovery and Pre-Clinical Stage Products, H1 2012 46
Assessment by Monotherapy Products, H1 2012 194
Assessment by Combination Products, H1 2012 195
Assessment by Route of Administration, H1 2012 196
Assessment by Stage and Route of Administration, H1 2012 197
Assessment by Molecule Type, H1 2012 199
Assessment by Stage and Molecule Type, H1 2012 200